Summary & Overview
HCPCS J0897: Denosumab Injection, 1 mg
HCPCS Level II code J0897 denotes a 1 mg unit of denosumab administered by injection. Denosumab is a monoclonal antibody therapy used in clinical management of conditions that require inhibition of bone resorption; billing for its units is a common element of oncology, endocrinology, and rheumatology care delivery. Nationally, accurate coding of J0897 matters for drug cost accounting, payer coverage determinations, and claim adjudication due to denosumab’s high per-unit cost and varied indications.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what J0897 represents, payer coverage context, and the types of benchmarks and policy details typically reviewed when evaluating injectable biologic drug codes. The publication presents clinical context about the service type and typical sites of service, common billing modifiers and payer considerations (listed separately), and where to look for relevant policy updates affecting biologic drug reimbursement.
This summary is intended to orient billing managers, revenue cycle leaders, and clinical administrators to the core billing identity of J0897, the payer landscape considered, and the topics addressed in the full publication, including reimbursement benchmarks, prior authorization trends, and coding guidance where available.
Billing Code Overview
HCPCS Level II code J0897 represents an injection of denosumab, 1 mg. The code denotes the unit of medication administered for denosumab, a monoclonal antibody used in clinical settings for conditions involving bone resorption.
-
Service type: Drug administration (injectable biologic)
-
Typical site of service: Ambulatory infusion clinic, physician office, hospital outpatient department, or other infusion settings where injectable biologic therapies are delivered
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 68-year-old postmenopausal woman with a history of osteoporosis and a recent fragility wrist fracture presents to the outpatient infusion clinic for administration of denosumab. The patient has dual-energy X-ray absorptiometry (DXA) confirming low bone mineral density and meets criteria for pharmacologic therapy. The clinic verifies allergies, recent calcium and vitamin D supplementation, and current serum calcium level prior to treatment. The registered nurse confirms informed consent and performs medication reconciliation, then prepares and administers the subcutaneous injection of denosumab. The encounter includes medication administration, post-injection observation for adverse reactions, documentation of lot number and dose, and scheduling of the next dose in six months.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug or biological amount discarded | When part of an expensive biologic vial is discarded and payor requires reporting of discarded drug units |
JZ | No drug or biological amount discarded | When the exact billed single-use syringe or vial was fully administered with no waste |